#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Genome-wide DNA methylation patterns and methylation abnormalities in pituitary tumors have been reported previously .
2-1	14-25	Genome-wide	abstract[4]	new[4]	_	_
2-2	26-29	DNA	abstract|abstract[4]	new|new[4]	coref	4-22
2-3	30-41	methylation	abstract|abstract[4]	new|new[4]	coref	2-6
2-4	42-50	patterns	abstract[4]	new[4]	_	_
2-5	51-54	and	_	_	_	_
2-6	55-66	methylation	abstract|abstract[6]	giv|new[6]	coref	3-9[11_0]
2-7	67-80	abnormalities	abstract[6]	new[6]	_	_
2-8	81-83	in	abstract[6]	new[6]	_	_
2-9	84-93	pituitary	abstract[6]|place|object[8]	new[6]|new|new[8]	coref|coref	4-33[0_8]|5-12
2-10	94-100	tumors	abstract[6]|object[8]	new[6]|new[8]	_	_
2-11	101-105	have	_	_	_	_
2-12	106-110	been	_	_	_	_
2-13	111-119	reported	_	_	_	_
2-14	120-130	previously	_	_	_	_
2-15	131-132	.	_	_	_	_

#Text=To date , however , the impact of aberrant CpG methylation on gene expression in NFPAs has not been investigated by a multi-omics approach .
3-1	133-135	To	_	_	_	_
3-2	136-140	date	time	new	_	_
3-3	141-142	,	_	_	_	_
3-4	143-150	however	_	_	_	_
3-5	151-152	,	_	_	_	_
3-6	153-156	the	abstract[10]	new[10]	_	_
3-7	157-163	impact	abstract[10]	new[10]	_	_
3-8	164-166	of	abstract[10]	new[10]	_	_
3-9	167-175	aberrant	abstract[10]|abstract[11]	new[10]|giv[11]	coref	4-22[26_11]
3-10	176-179	CpG	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
3-11	180-191	methylation	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
3-12	192-194	on	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
3-13	195-199	gene	abstract[10]|abstract[11]|abstract|abstract[13]	new[10]|giv[11]|new|new[13]	coref|coref	4-37[0_13]|9-9
3-14	200-210	expression	abstract[10]|abstract[11]|abstract[13]	new[10]|giv[11]|new[13]	_	_
3-15	211-213	in	abstract[10]|abstract[11]|abstract[13]	new[10]|giv[11]|new[13]	_	_
3-16	214-219	NFPAs	abstract[10]|abstract[11]|abstract[13]|object	new[10]|giv[11]|new[13]|new	coref	6-15
3-17	220-223	has	_	_	_	_
3-18	224-227	not	_	_	_	_
3-19	228-232	been	_	_	_	_
3-20	233-245	investigated	_	_	_	_
3-21	246-248	by	_	_	_	_
3-22	249-250	a	abstract[16]	new[16]	_	_
3-23	251-262	multi-omics	abstract|abstract[16]	new|new[16]	_	_
3-24	263-271	approach	abstract[16]	new[16]	_	_
3-25	272-273	.	_	_	_	_

#Text=In this study , we combined the results of methylome and transcriptome profiling of 33 gonadotroph NFPA samples to investigate whether DNA methylation at particular CpGs that are aberrantly methylated in gonadotroph tumors correlates with the expression levels of the corresponding genes .
4-1	274-276	In	_	_	_	_
4-2	277-281	this	abstract[17]	new[17]	coref	22-2[193_17]
4-3	282-287	study	abstract[17]	new[17]	_	_
4-4	288-289	,	_	_	_	_
4-5	290-292	we	person	acc	ana	6-2
4-6	293-301	combined	_	_	_	_
4-7	302-305	the	abstract[19]	new[19]	coref	15-1[127_19]
4-8	306-313	results	abstract[19]	new[19]	_	_
4-9	314-316	of	abstract[19]	new[19]	_	_
4-10	317-326	methylome	abstract[19]|abstract	new[19]|new	_	_
4-11	327-330	and	_	_	_	_
4-12	331-344	transcriptome	substance|object[22]	new|new[22]	_	_
4-13	345-354	profiling	object[22]	new[22]	_	_
4-14	355-357	of	object[22]	new[22]	_	_
4-15	358-360	33	object[22]|quantity[24]	new[22]|new[24]	_	_
4-16	361-372	gonadotroph	object[22]|quantity[24]	new[22]|new[24]	_	_
4-17	373-377	NFPA	object[22]|substance|quantity[24]	new[22]|new|new[24]	_	_
4-18	378-385	samples	object[22]|quantity[24]	new[22]|new[24]	_	_
4-19	386-388	to	_	_	_	_
4-20	389-400	investigate	_	_	_	_
4-21	401-408	whether	_	_	_	_
4-22	409-412	DNA	abstract|abstract[26]	giv|giv[26]	coref|coref	5-7|5-7[36_26]
4-23	413-424	methylation	abstract[26]	giv[26]	_	_
4-24	425-427	at	abstract[26]	giv[26]	_	_
4-25	428-438	particular	abstract[26]|abstract[27]	giv[26]|new[27]	coref	5-20[40_27]
4-26	439-443	CpGs	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
4-27	444-448	that	_	_	_	_
4-28	449-452	are	_	_	_	_
4-29	453-463	aberrantly	_	_	_	_
4-30	464-474	methylated	_	_	_	_
4-31	475-477	in	_	_	_	_
4-32	478-489	gonadotroph	person[29]	new[29]	_	_
4-33	490-496	tumors	object|person[29]	giv|new[29]	coref	6-25
4-34	497-507	correlates	person[29]	new[29]	_	_
4-35	508-512	with	_	_	_	_
4-36	513-516	the	abstract[31]	new[31]	_	_
4-37	517-527	expression	abstract|abstract[31]	giv|new[31]	coref	7-27[57_0]
4-38	528-534	levels	abstract[31]	new[31]	_	_
4-39	535-537	of	abstract[31]	new[31]	_	_
4-40	538-541	the	abstract[31]|abstract[32]	new[31]|new[32]	coref	6-19[46_32]
4-41	542-555	corresponding	abstract[31]|abstract[32]	new[31]|new[32]	_	_
4-42	556-561	genes	abstract[31]|abstract[32]	new[31]|new[32]	_	_
4-43	562-563	.	_	_	_	_

#Text=Gonadotroph NFPAs exhibited an increase in DNA methylation relative to normal pituitary sections , and a large number of differentially methylated CpGs have been identified .
5-1	564-575	Gonadotroph	person[33]	new[33]	_	_
5-2	576-581	NFPAs	person[33]	new[33]	_	_
5-3	582-591	exhibited	_	_	_	_
5-4	592-594	an	abstract[34]	new[34]	_	_
5-5	595-603	increase	abstract[34]	new[34]	_	_
5-6	604-606	in	abstract[34]	new[34]	_	_
5-7	607-610	DNA	abstract[34]|abstract|abstract[36]	new[34]|giv|giv[36]	coref|coref	7-5[50_36]|9-6
5-8	611-622	methylation	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
5-9	623-631	relative	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
5-10	632-634	to	_	_	_	_
5-11	635-641	normal	plant[38]	new[38]	coref	7-21[56_38]
5-12	642-651	pituitary	person|plant[38]	giv|new[38]	coref	7-21
5-13	652-660	sections	plant[38]	new[38]	_	_
5-14	661-662	,	_	_	_	_
5-15	663-666	and	_	_	_	_
5-16	667-668	a	abstract[39]	new[39]	_	_
5-17	669-674	large	abstract[39]	new[39]	_	_
5-18	675-681	number	abstract[39]	new[39]	_	_
5-19	682-684	of	abstract[39]	new[39]	_	_
5-20	685-699	differentially	abstract[39]|abstract[40]	new[39]|giv[40]	coref	6-9[0_40]
5-21	700-710	methylated	abstract[39]|abstract[40]	new[39]|giv[40]	_	_
5-22	711-715	CpGs	abstract[39]|abstract[40]	new[39]|giv[40]	_	_
5-23	716-720	have	_	_	_	_
5-24	721-725	been	_	_	_	_
5-25	726-736	identified	_	_	_	_
5-26	737-738	.	_	_	_	_

#Text=In our analysis , approximately 85 % of CpGs that are differentially methylated in NFPAs and associated with known human genes were hypermethylated in tumors .
6-1	739-741	In	_	_	_	_
6-2	742-745	our	person|abstract[42]	giv|new[42]	ana|coref	7-1|7-1[49_42]
6-3	746-754	analysis	abstract[42]	new[42]	_	_
6-4	755-756	,	_	_	_	_
6-5	757-770	approximately	quantity[43]	new[43]	_	_
6-6	771-773	85	quantity[43]	new[43]	_	_
6-7	774-775	%	quantity[43]	new[43]	_	_
6-8	776-778	of	quantity[43]	new[43]	_	_
6-9	779-783	CpGs	quantity[43]|abstract	new[43]|giv	coref	7-12
6-10	784-788	that	_	_	_	_
6-11	789-792	are	_	_	_	_
6-12	793-807	differentially	_	_	_	_
6-13	808-818	methylated	_	_	_	_
6-14	819-821	in	_	_	_	_
6-15	822-827	NFPAs	substance	giv	coref	22-11
6-16	828-831	and	_	_	_	_
6-17	832-842	associated	_	_	_	_
6-18	843-847	with	_	_	_	_
6-19	848-853	known	abstract[46]	giv[46]	coref	7-30[58_46]
6-20	854-859	human	abstract[46]	giv[46]	_	_
6-21	860-865	genes	abstract[46]	giv[46]	_	_
6-22	866-870	were	_	_	_	_
6-23	871-886	hypermethylated	_	_	_	_
6-24	887-889	in	_	_	_	_
6-25	890-896	tumors	object	giv	coref	10-45[89_0]
6-26	897-898	.	_	_	_	_

#Text=Our correlation-based analysis revealed that methylation of a major fraction of CpGs that are differentially methylated in gonadotroph adenomas and pituitary sections did not correlate with the expression of the annotated genes .
7-1	899-902	Our	person|abstract[49]	giv|giv[49]	coref|ana	8-7[60_49]|9-1
7-2	903-920	correlation-based	abstract[49]	giv[49]	_	_
7-3	921-929	analysis	abstract[49]	giv[49]	_	_
7-4	930-938	revealed	_	_	_	_
7-5	939-943	that	abstract[50]	giv[50]	coref	9-6[65_50]
7-6	944-955	methylation	abstract[50]	giv[50]	_	_
7-7	956-958	of	abstract[50]	giv[50]	_	_
7-8	959-960	a	abstract[50]|quantity[51]	giv[50]|new[51]	_	_
7-9	961-966	major	abstract[50]|quantity[51]	giv[50]|new[51]	_	_
7-10	967-975	fraction	abstract[50]|quantity[51]	giv[50]|new[51]	_	_
7-11	976-978	of	abstract[50]|quantity[51]	giv[50]|new[51]	_	_
7-12	979-983	CpGs	abstract[50]|quantity[51]|abstract	giv[50]|new[51]|giv	coref	9-16[70_0]
7-13	984-988	that	_	_	_	_
7-14	989-992	are	_	_	_	_
7-15	993-1007	differentially	_	_	_	_
7-16	1008-1018	methylated	_	_	_	_
7-17	1019-1021	in	_	_	_	_
7-18	1022-1033	gonadotroph	place[53]|object[54]	new[53]|new[54]	coref|coref	10-22[80_53]|10-22[81_54]
7-19	1034-1042	adenomas	place[53]|object[54]	new[53]|new[54]	_	_
7-20	1043-1046	and	object[54]	new[54]	_	_
7-21	1047-1056	pituitary	object[54]|person|plant[56]	new[54]|giv|giv[56]	coref|coref	10-22|22-13[200_56]
7-22	1057-1065	sections	object[54]|plant[56]	new[54]|giv[56]	_	_
7-23	1066-1069	did	_	_	_	_
7-24	1070-1073	not	_	_	_	_
7-25	1074-1083	correlate	_	_	_	_
7-26	1084-1088	with	_	_	_	_
7-27	1089-1092	the	abstract[57]	giv[57]	ana	8-1[0_57]
7-28	1093-1103	expression	abstract[57]	giv[57]	_	_
7-29	1104-1106	of	abstract[57]	giv[57]	_	_
7-30	1107-1110	the	abstract[57]|abstract[58]	giv[57]|giv[58]	coref	10-9[0_58]
7-31	1111-1120	annotated	abstract[57]|abstract[58]	giv[57]|giv[58]	_	_
7-32	1121-1126	genes	abstract[57]|abstract[58]	giv[57]|giv[58]	_	_
7-33	1127-1128	.	_	_	_	_

#Text=This has also been observed in a similar analysis of other human cancers .
8-1	1129-1133	This	abstract	giv	coref	9-9[68_0]
8-2	1134-1137	has	_	_	_	_
8-3	1138-1142	also	_	_	_	_
8-4	1143-1147	been	_	_	_	_
8-5	1148-1156	observed	_	_	_	_
8-6	1157-1159	in	_	_	_	_
8-7	1160-1161	a	abstract[60]	giv[60]	coref	28-4[261_60]
8-8	1162-1169	similar	abstract[60]	giv[60]	_	_
8-9	1170-1178	analysis	abstract[60]	giv[60]	_	_
8-10	1179-1181	of	abstract[60]	giv[60]	_	_
8-11	1182-1187	other	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
8-12	1188-1193	human	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
8-13	1194-1201	cancers	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
8-14	1202-1203	.	_	_	_	_

#Text=We observed a correlation between DNA methylation and gene expression in approximately 11 % of gene-associated CpGs with aberrant DNA methylation .
9-1	1204-1206	We	person	giv	ana	17-9
9-2	1207-1215	observed	_	_	_	_
9-3	1216-1217	a	abstract[63]	new[63]	coref	11-1[93_63]
9-4	1218-1229	correlation	abstract[63]	new[63]	_	_
9-5	1230-1237	between	abstract[63]	new[63]	_	_
9-6	1238-1241	DNA	abstract[63]|abstract|abstract[65]|abstract[66]	new[63]|giv|giv[65]|new[66]	coref|coref|coref	9-20|9-19[72_65]|10-12[77_66]
9-7	1242-1253	methylation	abstract[63]|abstract[65]|abstract[66]	new[63]|giv[65]|new[66]	_	_
9-8	1254-1257	and	abstract[63]|abstract[66]	new[63]|new[66]	_	_
9-9	1258-1262	gene	abstract[63]|abstract[66]|abstract|abstract[68]	new[63]|new[66]|giv|giv[68]	coref|coref	10-14[0_68]|13-9
9-10	1263-1273	expression	abstract[63]|abstract[66]|abstract[68]	new[63]|new[66]|giv[68]	_	_
9-11	1274-1276	in	abstract[63]	new[63]	_	_
9-12	1277-1290	approximately	abstract[63]|quantity[69]	new[63]|new[69]	_	_
9-13	1291-1293	11	abstract[63]|quantity[69]	new[63]|new[69]	_	_
9-14	1294-1295	%	abstract[63]|quantity[69]	new[63]|new[69]	_	_
9-15	1296-1298	of	abstract[63]|quantity[69]	new[63]|new[69]	_	_
9-16	1299-1314	gene-associated	abstract[63]|quantity[69]|abstract[70]	new[63]|new[69]|giv[70]	coref	12-14[109_70]
9-17	1315-1319	CpGs	abstract[63]|quantity[69]|abstract[70]	new[63]|new[69]|giv[70]	_	_
9-18	1320-1324	with	abstract[63]|quantity[69]|abstract[70]	new[63]|new[69]|giv[70]	_	_
9-19	1325-1333	aberrant	abstract[63]|quantity[69]|abstract[70]|abstract[72]	new[63]|new[69]|giv[70]|giv[72]	coref	10-12[0_72]
9-20	1334-1337	DNA	abstract[63]|quantity[69]|abstract[70]|abstract|abstract[72]	new[63]|new[69]|giv[70]|giv|giv[72]	coref	11-5
9-21	1338-1349	methylation	abstract[63]|quantity[69]|abstract[70]|abstract[72]	new[63]|new[69]|giv[70]|giv[72]	_	_
9-22	1350-1351	.	_	_	_	_

#Text=These CpG sites are located in or near genes for which methylation and expression were previously reported to be correlated in pituitary adenomas , including STAT5A , RHOD , GALNT9 , and RASSF1 , as well as genes with previously described aberrant methylation in pituitary tumors , including CDKN1A , TP73 , and STAT3 .
10-1	1352-1357	These	place[74]	new[74]	coref	14-2[121_74]
10-2	1358-1361	CpG	abstract|place[74]	new|new[74]	_	_
10-3	1362-1367	sites	place[74]	new[74]	_	_
10-4	1368-1371	are	_	_	_	_
10-5	1372-1379	located	_	_	_	_
10-6	1380-1382	in	_	_	_	_
10-7	1383-1385	or	_	_	_	_
10-8	1386-1390	near	_	_	_	_
10-9	1391-1396	genes	abstract	giv	coref	10-38[86_0]
10-10	1397-1400	for	_	_	_	_
10-11	1401-1406	which	_	_	_	_
10-12	1407-1418	methylation	abstract|abstract[77]	giv|giv[77]	coref|coref	10-40[87_0]|11-4[96_77]
10-13	1419-1422	and	abstract[77]	giv[77]	_	_
10-14	1423-1433	expression	abstract[77]|abstract	giv[77]|giv	coref	11-9
10-15	1434-1438	were	_	_	_	_
10-16	1439-1449	previously	_	_	_	_
10-17	1450-1458	reported	_	_	_	_
10-18	1459-1461	to	_	_	_	_
10-19	1462-1464	be	_	_	_	_
10-20	1465-1475	correlated	_	_	_	_
10-21	1476-1478	in	_	_	_	_
10-22	1479-1488	pituitary	person|place[80]|object[81]	giv|giv[80]|giv[81]	coref	10-45
10-23	1489-1497	adenomas	place[80]|object[81]	giv[80]|giv[81]	_	_
10-24	1498-1499	,	place[80]|object[81]	giv[80]|giv[81]	_	_
10-25	1500-1509	including	place[80]|object[81]	giv[80]|giv[81]	_	_
10-26	1510-1516	STAT5A	place[80]|object[81]|abstract	giv[80]|giv[81]|new	_	_
10-27	1517-1518	,	place[80]|object[81]	giv[80]|giv[81]	_	_
10-28	1519-1523	RHOD	place[80]|object[81]|abstract	giv[80]|giv[81]|new	_	_
10-29	1524-1525	,	place[80]|object[81]	giv[80]|giv[81]	_	_
10-30	1526-1532	GALNT9	place[80]|object[81]|abstract	giv[80]|giv[81]|new	_	_
10-31	1533-1534	,	place[80]|object[81]	giv[80]|giv[81]	_	_
10-32	1535-1538	and	place[80]|object[81]	giv[80]|giv[81]	_	_
10-33	1539-1545	RASSF1	place[80]|object[81]|abstract	giv[80]|giv[81]|new	_	_
10-34	1546-1547	,	object[81]	giv[81]	_	_
10-35	1548-1550	as	object[81]	giv[81]	_	_
10-36	1551-1555	well	object[81]	giv[81]	_	_
10-37	1556-1558	as	object[81]	giv[81]	_	_
10-38	1559-1564	genes	object[81]|abstract[86]	giv[81]|giv[86]	coref	12-4[0_86]
10-39	1565-1569	with	object[81]|abstract[86]	giv[81]|giv[86]	_	_
10-40	1570-1580	previously	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	coref	11-4[95_87]
10-41	1581-1590	described	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-42	1591-1599	aberrant	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-43	1600-1611	methylation	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-44	1612-1614	in	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-45	1615-1624	pituitary	object[81]|abstract[86]|abstract[87]|place|object[89]	giv[81]|giv[86]|giv[87]|giv|giv[89]	coref|coref	11-26|11-26[103_89]
10-46	1625-1631	tumors	object[81]|abstract[86]|abstract[87]|object[89]	giv[81]|giv[86]|giv[87]|giv[89]	_	_
10-47	1632-1633	,	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-48	1634-1643	including	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-49	1644-1650	CDKN1A	object[81]|abstract[86]|abstract[87]|object	giv[81]|giv[86]|giv[87]|new	_	_
10-50	1651-1652	,	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-51	1653-1657	TP73	object[81]|abstract[86]|abstract[87]|abstract	giv[81]|giv[86]|giv[87]|new	_	_
10-52	1658-1659	,	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-53	1660-1663	and	object[81]|abstract[86]|abstract[87]	giv[81]|giv[86]|giv[87]	_	_
10-54	1664-1669	STAT3	object[81]|abstract[86]|abstract[87]|abstract	giv[81]|giv[86]|giv[87]|new	_	_
10-55	1670-1671	.	_	_	_	_

#Text=A correlation between aberrant DNA methylation and the expression level was also observed for HMGA2 , which plays an important role in the pathogenesis of pituitary tumors .
11-1	1672-1673	A	abstract[93]	giv[93]	coref	17-85[167_93]
11-2	1674-1685	correlation	abstract[93]	giv[93]	_	_
11-3	1686-1693	between	abstract[93]	giv[93]	_	_
11-4	1694-1702	aberrant	abstract[93]|abstract[95]|abstract[96]	giv[93]|giv[95]|giv[96]	coref|coref	12-11[0_95]|17-79[165_96]
11-5	1703-1706	DNA	abstract[93]|substance|abstract[95]|abstract[96]	giv[93]|giv|giv[95]|giv[96]	coref	21-30
11-6	1707-1718	methylation	abstract[93]|abstract[95]|abstract[96]	giv[93]|giv[95]|giv[96]	_	_
11-7	1719-1722	and	abstract[93]|abstract[96]	giv[93]|giv[96]	_	_
11-8	1723-1726	the	abstract[93]|abstract[96]|abstract[98]	giv[93]|giv[96]|new[98]	coref	12-10[108_98]
11-9	1727-1737	expression	abstract[93]|abstract[96]|abstract|abstract[98]	giv[93]|giv[96]|giv|new[98]	coref	12-5[106_0]
11-10	1738-1743	level	abstract[93]|abstract[96]|abstract[98]	giv[93]|giv[96]|new[98]	_	_
11-11	1744-1747	was	_	_	_	_
11-12	1748-1752	also	_	_	_	_
11-13	1753-1761	observed	_	_	_	_
11-14	1762-1765	for	_	_	_	_
11-15	1766-1771	HMGA2	abstract	new	_	_
11-16	1772-1773	,	_	_	_	_
11-17	1774-1779	which	_	_	_	_
11-18	1780-1785	plays	_	_	_	_
11-19	1786-1788	an	abstract[100]	new[100]	_	_
11-20	1789-1798	important	abstract[100]	new[100]	_	_
11-21	1799-1803	role	abstract[100]	new[100]	_	_
11-22	1804-1806	in	_	_	_	_
11-23	1807-1810	the	event[101]	new[101]	_	_
11-24	1811-1823	pathogenesis	event[101]	new[101]	_	_
11-25	1824-1826	of	event[101]	new[101]	_	_
11-26	1827-1836	pituitary	event[101]|place|object[103]	new[101]|giv|giv[103]	coref|coref	15-12[0_103]|22-14
11-27	1837-1843	tumors	event[101]|object[103]	new[101]|giv[103]	_	_
11-28	1844-1845	.	_	_	_	_

#Text=GSEA revealed that genes whose expression was related to the methylation level of differentially methylated CpGs were enriched in pathways and processes important for tumor development .
12-1	1846-1850	GSEA	event	new	coref	26-6[243_0]
12-2	1851-1859	revealed	_	_	_	_
12-3	1860-1864	that	_	_	_	_
12-4	1865-1870	genes	abstract	giv	coref	15-28
12-5	1871-1876	whose	abstract[106]	giv[106]	coref	13-9[117_106]
12-6	1877-1887	expression	abstract[106]	giv[106]	_	_
12-7	1888-1891	was	_	_	_	_
12-8	1892-1899	related	_	_	_	_
12-9	1900-1902	to	_	_	_	_
12-10	1903-1906	the	abstract[108]	giv[108]	_	_
12-11	1907-1918	methylation	abstract|abstract[108]	giv|giv[108]	coref	13-4[115_0]
12-12	1919-1924	level	abstract[108]	giv[108]	_	_
12-13	1925-1927	of	abstract[108]	giv[108]	_	_
12-14	1928-1942	differentially	abstract[108]|abstract[109]	giv[108]|giv[109]	coref	13-2[114_109]
12-15	1943-1953	methylated	abstract[108]|abstract[109]	giv[108]|giv[109]	_	_
12-16	1954-1958	CpGs	abstract[108]|abstract[109]	giv[108]|giv[109]	_	_
12-17	1959-1963	were	_	_	_	_
12-18	1964-1972	enriched	_	_	_	_
12-19	1973-1975	in	_	_	_	_
12-20	1976-1984	pathways	abstract	new	_	_
12-21	1985-1988	and	_	_	_	_
12-22	1989-1998	processes	abstract[111]	new[111]	_	_
12-23	1999-2008	important	abstract[111]	new[111]	_	_
12-24	2009-2012	for	_	_	_	_
12-25	2013-2018	tumor	abstract|event[113]	new|new[113]	_	_
12-26	2019-2030	development	event[113]	new[113]	_	_
12-27	2031-2032	.	_	_	_	_

#Text=For most CpGs whose methylation was related to gene expression , the relationship was an inverse one :
13-1	2033-2036	For	_	_	_	_
13-2	2037-2041	most	abstract[114]	giv[114]	coref	17-14[143_114]
13-3	2042-2046	CpGs	abstract[114]	giv[114]	_	_
13-4	2047-2052	whose	abstract[115]	giv[115]	coref	15-14[130_115]
13-5	2053-2064	methylation	abstract[115]	giv[115]	_	_
13-6	2065-2068	was	_	_	_	_
13-7	2069-2076	related	_	_	_	_
13-8	2077-2079	to	_	_	_	_
13-9	2080-2084	gene	abstract|abstract[117]	giv|giv[117]	coref|coref	14-15|14-15[126_117]
13-10	2085-2095	expression	abstract[117]	giv[117]	_	_
13-11	2096-2097	,	_	_	_	_
13-12	2098-2101	the	abstract[118]	new[118]	_	_
13-13	2102-2114	relationship	abstract[118]	new[118]	_	_
13-14	2115-2118	was	_	_	_	_
13-15	2119-2121	an	abstract[120]	new[120]	_	_
13-16	2122-2129	inverse	place|abstract[120]	new|new[120]	_	_
13-17	2130-2133	one	abstract[120]	new[120]	_	_
13-18	2134-2135	:	_	_	_	_

#Text=For these sites , hypermethylation and hypomethylation corresponded to a decrease and increase in gene expression , respectively .
14-1	2136-2139	For	_	_	_	_
14-2	2140-2145	these	place[121]	giv[121]	_	_
14-3	2146-2151	sites	place[121]	giv[121]	_	_
14-4	2152-2153	,	_	_	_	_
14-5	2154-2170	hypermethylation	abstract	new	_	_
14-6	2171-2174	and	_	_	_	_
14-7	2175-2190	hypomethylation	abstract	new	coref	16-6
14-8	2191-2203	corresponded	_	_	_	_
14-9	2204-2206	to	_	_	_	_
14-10	2207-2208	a	event[124]	new[124]	_	_
14-11	2209-2217	decrease	event[124]	new[124]	_	_
14-12	2218-2221	and	_	_	_	_
14-13	2222-2230	increase	_	_	_	_
14-14	2231-2233	in	_	_	_	_
14-15	2234-2238	gene	abstract|abstract[126]	giv|giv[126]	coref|coref	17-31|17-81[0_126]
14-16	2239-2249	expression	abstract[126]	giv[126]	_	_
14-17	2250-2251	,	_	_	_	_
14-18	2252-2264	respectively	_	_	_	_
14-19	2265-2266	.	_	_	_	_

#Text=These results are generally in line with the idea that in tumors , elevated methylation is associated with transcriptional silencing , providing a mechanism for inactivation of genes with tumor-suppressor function .
15-1	2267-2272	These	abstract[127]	giv[127]	coref	17-6[140_127]
15-2	2273-2280	results	abstract[127]	giv[127]	_	_
15-3	2281-2284	are	_	_	_	_
15-4	2285-2294	generally	_	_	_	_
15-5	2295-2297	in	_	_	_	_
15-6	2298-2302	line	_	_	_	_
15-7	2303-2307	with	_	_	_	_
15-8	2308-2311	the	abstract[128]	new[128]	_	_
15-9	2312-2316	idea	abstract[128]	new[128]	_	_
15-10	2317-2321	that	_	_	_	_
15-11	2322-2324	in	_	_	_	_
15-12	2325-2331	tumors	object	giv	coref	24-50
15-13	2332-2333	,	_	_	_	_
15-14	2334-2342	elevated	abstract[130]	giv[130]	coref	17-79[0_130]
15-15	2343-2354	methylation	abstract[130]	giv[130]	_	_
15-16	2355-2357	is	_	_	_	_
15-17	2358-2368	associated	_	_	_	_
15-18	2369-2373	with	_	_	_	_
15-19	2374-2389	transcriptional	abstract[131]	new[131]	_	_
15-20	2390-2399	silencing	abstract[131]	new[131]	_	_
15-21	2400-2401	,	_	_	_	_
15-22	2402-2411	providing	_	_	_	_
15-23	2412-2413	a	abstract[132]	new[132]	coref	27-19[252_132]
15-24	2414-2423	mechanism	abstract[132]	new[132]	_	_
15-25	2424-2427	for	abstract[132]	new[132]	_	_
15-26	2428-2440	inactivation	abstract[132]|event[133]	new[132]|new[133]	_	_
15-27	2441-2443	of	abstract[132]|event[133]	new[132]|new[133]	_	_
15-28	2444-2449	genes	abstract[132]|event[133]|abstract	new[132]|new[133]|giv	coref	21-8[182_0]
15-29	2450-2454	with	abstract[132]|event[133]	new[132]|new[133]	_	_
15-30	2455-2471	tumor-suppressor	abstract[132]|event[133]|abstract[135]	new[132]|new[133]|new[135]	_	_
15-31	2472-2480	function	abstract[132]|event[133]|abstract[135]	new[132]|new[133]|new[135]	_	_
15-32	2481-2482	.	_	_	_	_

#Text=On the other hand , hypomethylation may result in the activation of potential oncogenes .
16-1	2483-2485	On	_	_	_	_
16-2	2486-2489	the	_	_	_	_
16-3	2490-2495	other	_	_	_	_
16-4	2496-2500	hand	_	_	_	_
16-5	2501-2502	,	_	_	_	_
16-6	2503-2518	hypomethylation	abstract	giv	_	_
16-7	2519-2522	may	_	_	_	_
16-8	2523-2529	result	_	_	_	_
16-9	2530-2532	in	_	_	_	_
16-10	2533-2536	the	event[137]	new[137]	_	_
16-11	2537-2547	activation	event[137]	new[137]	_	_
16-12	2548-2550	of	event[137]	new[137]	_	_
16-13	2551-2560	potential	event[137]|substance[138]	new[137]|new[138]	_	_
16-14	2561-2570	oncogenes	event[137]|substance[138]	new[137]|new[138]	_	_
16-15	2571-2572	.	_	_	_	_

#Text=To simplify the interpretation of the results , we distinguished two classes of aberrantly methylated CpGs : Those in promoters , i. e. , located in the 5 ’ promoter gene region , which includes regions from 1500 bp upstream of the TSS up to the first exon of the gene , and those in gene bodies , including exons , introns , and 3’UTR sequences . For 81 % of the CpGs located in promoters for which methylation and expression were correlated , the correlation was negative , in concordance with the overall model .
17-1	2573-2575	To	_	_	_	_
17-2	2576-2584	simplify	_	_	_	_
17-3	2585-2588	the	abstract[139]	new[139]	_	_
17-4	2589-2603	interpretation	abstract[139]	new[139]	_	_
17-5	2604-2606	of	abstract[139]	new[139]	_	_
17-6	2607-2610	the	abstract[139]|abstract[140]	new[139]|giv[140]	_	_
17-7	2611-2618	results	abstract[139]|abstract[140]	new[139]|giv[140]	_	_
17-8	2619-2620	,	_	_	_	_
17-9	2621-2623	we	person	giv	ana	22-5
17-10	2624-2637	distinguished	_	_	_	_
17-11	2638-2641	two	person[142]	new[142]	_	_
17-12	2642-2649	classes	person[142]	new[142]	_	_
17-13	2650-2652	of	person[142]	new[142]	_	_
17-14	2653-2663	aberrantly	person[142]|abstract[143]	new[142]|giv[143]	coref	17-72[162_143]
17-15	2664-2674	methylated	person[142]|abstract[143]	new[142]|giv[143]	_	_
17-16	2675-2679	CpGs	person[142]|abstract[143]	new[142]|giv[143]	_	_
17-17	2680-2681	:	_	_	_	_
17-18	2682-2687	Those	_	_	_	_
17-19	2688-2690	in	_	_	_	_
17-20	2691-2700	promoters	person	new	coref	17-76
17-21	2701-2702	,	_	_	_	_
17-22	2703-2705	i.	_	_	_	_
17-23	2706-2708	e.	_	_	_	_
17-24	2709-2710	,	_	_	_	_
17-25	2711-2718	located	_	_	_	_
17-26	2719-2721	in	_	_	_	_
17-27	2722-2725	the	place[148]	new[148]	_	_
17-28	2726-2727	5	quantity[145]|place[148]	new[145]|new[148]	_	_
17-29	2728-2729	’	quantity[145]|place[148]	new[145]|new[148]	_	_
17-30	2730-2738	promoter	person|place[148]	new|new[148]	coref	21-23
17-31	2739-2743	gene	abstract|place[148]	giv|new[148]	coref	17-50[154_0]
17-32	2744-2750	region	place[148]	new[148]	_	_
17-33	2751-2752	,	_	_	_	_
17-34	2753-2758	which	_	_	_	_
17-35	2759-2767	includes	_	_	_	_
17-36	2768-2775	regions	place[149]	new[149]	_	_
17-37	2776-2780	from	place[149]	new[149]	_	_
17-38	2781-2785	1500	place[149]|place[151]	new[149]|new[151]	_	_
17-39	2786-2788	bp	place[149]|abstract|place[151]	new[149]|new|new[151]	_	_
17-40	2789-2797	upstream	place[149]|place[151]	new[149]|new[151]	_	_
17-41	2798-2800	of	place[149]|place[151]	new[149]|new[151]	_	_
17-42	2801-2804	the	place[149]|place[151]|abstract[152]	new[149]|new[151]|new[152]	_	_
17-43	2805-2808	TSS	place[149]|place[151]|abstract[152]	new[149]|new[151]|new[152]	_	_
17-44	2809-2811	up	place[149]|place[151]|abstract[152]	new[149]|new[151]|new[152]	_	_
17-45	2812-2814	to	place[149]|place[151]	new[149]|new[151]	_	_
17-46	2815-2818	the	place[149]|place[151]|abstract[153]	new[149]|new[151]|new[153]	_	_
17-47	2819-2824	first	place[149]|place[151]|abstract[153]	new[149]|new[151]|new[153]	_	_
17-48	2825-2829	exon	place[149]|place[151]|abstract[153]	new[149]|new[151]|new[153]	_	_
17-49	2830-2832	of	place[149]|place[151]|abstract[153]	new[149]|new[151]|new[153]	_	_
17-50	2833-2836	the	place[149]|place[151]|abstract[153]|abstract[154]	new[149]|new[151]|new[153]|giv[154]	coref	17-56[0_154]
17-51	2837-2841	gene	place[149]|place[151]|abstract[153]|abstract[154]	new[149]|new[151]|new[153]|giv[154]	_	_
17-52	2842-2843	,	place[149]|place[151]	new[149]|new[151]	_	_
17-53	2844-2847	and	place[149]|place[151]	new[149]|new[151]	_	_
17-54	2848-2853	those	place[149]|place[151]	new[149]|new[151]	_	_
17-55	2854-2856	in	place[149]|place[151]	new[149]|new[151]	_	_
17-56	2857-2861	gene	place[149]|place[151]|abstract|object[156]	new[149]|new[151]|giv|new[156]	coref|coref	20-9|20-9[176_156]
17-57	2862-2868	bodies	place[149]|place[151]|object[156]	new[149]|new[151]|new[156]	_	_
17-58	2869-2870	,	place[149]|place[151]|object[156]	new[149]|new[151]|new[156]	_	_
17-59	2871-2880	including	place[149]|place[151]|object[156]	new[149]|new[151]|new[156]	_	_
17-60	2881-2886	exons	place[149]|place[151]|object[156]|abstract	new[149]|new[151]|new[156]|new	_	_
17-61	2887-2888	,	place[149]|place[151]|object[156]	new[149]|new[151]|new[156]	_	_
17-62	2889-2896	introns	place[149]|place[151]|object[156]|person	new[149]|new[151]|new[156]|new	_	_
17-63	2897-2898	,	place[149]|place[151]|object[156]	new[149]|new[151]|new[156]	_	_
17-64	2899-2902	and	place[149]|place[151]|object[156]	new[149]|new[151]|new[156]	_	_
17-65	2903-2908	3’UTR	place[149]|place[151]|object[156]|abstract|abstract[160]	new[149]|new[151]|new[156]|new|new[160]	_	_
17-66	2909-2918	sequences	place[149]|place[151]|object[156]|abstract[160]	new[149]|new[151]|new[156]|new[160]	_	_
17-67	2919-2920	.	place[149]|place[151]|object[156]|abstract[160]	new[149]|new[151]|new[156]|new[160]	_	_
17-68	2921-2924	For	place[149]|place[151]|object[156]|abstract[160]	new[149]|new[151]|new[156]|new[160]	_	_
17-69	2925-2927	81	place[149]|place[151]|object[156]|abstract[160]|quantity[161]	new[149]|new[151]|new[156]|new[160]|new[161]	_	_
17-70	2928-2929	%	place[149]|place[151]|object[156]|abstract[160]|quantity[161]	new[149]|new[151]|new[156]|new[160]|new[161]	_	_
17-71	2930-2932	of	place[149]|place[151]|object[156]|abstract[160]|quantity[161]	new[149]|new[151]|new[156]|new[160]|new[161]	_	_
17-72	2933-2936	the	place[149]|place[151]|object[156]|abstract[160]|quantity[161]|abstract[162]	new[149]|new[151]|new[156]|new[160]|new[161]|giv[162]	coref	19-1[0_162]
17-73	2937-2941	CpGs	place[149]|place[151]|object[156]|abstract[160]|quantity[161]|abstract[162]	new[149]|new[151]|new[156]|new[160]|new[161]|giv[162]	_	_
17-74	2942-2949	located	_	_	_	_
17-75	2950-2952	in	_	_	_	_
17-76	2953-2962	promoters	person	giv	coref	20-19
17-77	2963-2966	for	_	_	_	_
17-78	2967-2972	which	_	_	_	_
17-79	2973-2984	methylation	abstract|abstract[165]	giv|giv[165]	coref|coref	21-1[181_0]|25-20[235_165]
17-80	2985-2988	and	abstract[165]	giv[165]	_	_
17-81	2989-2999	expression	abstract[165]|abstract	giv[165]|giv	coref	19-15[173_0]
17-82	3000-3004	were	_	_	_	_
17-83	3005-3015	correlated	_	_	_	_
17-84	3016-3017	,	_	_	_	_
17-85	3018-3021	the	abstract[167]	giv[167]	coref	24-9[215_167]
17-86	3022-3033	correlation	abstract[167]	giv[167]	_	_
17-87	3034-3037	was	_	_	_	_
17-88	3038-3046	negative	_	_	_	_
17-89	3047-3048	,	_	_	_	_
17-90	3049-3051	in	_	_	_	_
17-91	3052-3063	concordance	abstract[168]	new[168]	_	_
17-92	3064-3068	with	abstract[168]	new[168]	_	_
17-93	3069-3072	the	abstract[168]|abstract[169]	new[168]|new[169]	_	_
17-94	3073-3080	overall	abstract[168]|abstract[169]	new[168]|new[169]	_	_
17-95	3081-3086	model	abstract[168]|abstract[169]	new[168]|new[169]	_	_
17-96	3087-3088	.	_	_	_	_

#Text=Approximately one-third of all methylation/expression-correlated
18-1	3089-3102	Approximately	quantity[170]	new[170]	_	_
18-2	3103-3112	one-third	quantity[170]	new[170]	_	_
18-3	3113-3115	of	quantity[170]	new[170]	_	_
18-4	3116-3119	all	quantity[170]|abstract[171]	new[170]|new[171]	_	_
18-5	3120-3153	methylation/expression-correlated	quantity[170]|abstract[171]	new[170]|new[171]	_	_

#Text=CpGs were positively correlated , i. e. , hypermethylation and hypomethylation were associated with increased and decreased expression , respectively .
19-1	3154-3158	CpGs	abstract	giv	coref	20-2[174_0]
19-2	3159-3163	were	_	_	_	_
19-3	3164-3174	positively	_	_	_	_
19-4	3175-3185	correlated	_	_	_	_
19-5	3186-3187	,	_	_	_	_
19-6	3188-3190	i.	_	_	_	_
19-7	3191-3193	e.	_	_	_	_
19-8	3194-3195	,	_	_	_	_
19-9	3196-3212	hypermethylation	_	_	_	_
19-10	3213-3216	and	_	_	_	_
19-11	3217-3232	hypomethylation	_	_	_	_
19-12	3233-3237	were	_	_	_	_
19-13	3238-3248	associated	_	_	_	_
19-14	3249-3253	with	_	_	_	_
19-15	3254-3263	increased	abstract[173]	giv[173]	coref	21-20[186_173]
19-16	3264-3267	and	abstract[173]	giv[173]	_	_
19-17	3268-3277	decreased	abstract[173]	giv[173]	_	_
19-18	3278-3288	expression	abstract[173]	giv[173]	_	_
19-19	3289-3290	,	_	_	_	_
19-20	3291-3303	respectively	_	_	_	_
19-21	3304-3305	.	_	_	_	_

#Text=Among these CpGs , most are located in gene bodies , whereas only 22 % are located in promoters , consistent with previously published reports .
20-1	3306-3311	Among	_	_	_	_
20-2	3312-3317	these	abstract[174]	giv[174]	_	_
20-3	3318-3322	CpGs	abstract[174]	giv[174]	_	_
20-4	3323-3324	,	_	_	_	_
20-5	3325-3329	most	_	_	_	_
20-6	3330-3333	are	_	_	_	_
20-7	3334-3341	located	_	_	_	_
20-8	3342-3344	in	_	_	_	_
20-9	3345-3349	gene	abstract|object[176]	giv|giv[176]	coref|coref	21-20|21-33[191_176]
20-10	3350-3356	bodies	object[176]	giv[176]	_	_
20-11	3357-3358	,	_	_	_	_
20-12	3359-3366	whereas	_	_	_	_
20-13	3367-3371	only	quantity[177]	new[177]	_	_
20-14	3372-3374	22	quantity[177]	new[177]	_	_
20-15	3375-3376	%	quantity[177]	new[177]	_	_
20-16	3377-3380	are	_	_	_	_
20-17	3381-3388	located	_	_	_	_
20-18	3389-3391	in	_	_	_	_
20-19	3392-3401	promoters	place	giv	_	_
20-20	3402-3403	,	_	_	_	_
20-21	3404-3414	consistent	_	_	_	_
20-22	3415-3419	with	_	_	_	_
20-23	3420-3430	previously	abstract[179]	new[179]	_	_
20-24	3431-3440	published	abstract[179]	new[179]	_	_
20-25	3441-3448	reports	abstract[179]	new[179]	_	_
20-26	3449-3450	.	_	_	_	_

#Text=Gene body methylation has been observed in active genes , implying that it may have the opposite effect on gene expression to promoter methylation , i. e. , increased DNA methylation in gene bodies may promote transcription .
21-1	3451-3455	Gene	abstract[181]	giv[181]	ana	21-13[0_181]
21-2	3456-3460	body	object|abstract[181]	new|giv[181]	_	_
21-3	3461-3472	methylation	abstract[181]	giv[181]	_	_
21-4	3473-3476	has	_	_	_	_
21-5	3477-3481	been	_	_	_	_
21-6	3482-3490	observed	_	_	_	_
21-7	3491-3493	in	_	_	_	_
21-8	3494-3500	active	abstract[182]	giv[182]	coref	23-11[209_182]
21-9	3501-3506	genes	abstract[182]	giv[182]	_	_
21-10	3507-3508	,	_	_	_	_
21-11	3509-3517	implying	_	_	_	_
21-12	3518-3522	that	_	_	_	_
21-13	3523-3525	it	abstract	giv	coref	21-23[188_0]
21-14	3526-3529	may	_	_	_	_
21-15	3530-3534	have	_	_	_	_
21-16	3535-3538	the	abstract[184]	new[184]	_	_
21-17	3539-3547	opposite	abstract[184]	new[184]	_	_
21-18	3548-3554	effect	abstract[184]	new[184]	_	_
21-19	3555-3557	on	abstract[184]	new[184]	_	_
21-20	3558-3562	gene	abstract[184]|abstract|abstract[186]	new[184]|giv|giv[186]	coref|coref	22-8[0_186]|24-38[224_0]
21-21	3563-3573	expression	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
21-22	3574-3576	to	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
21-23	3577-3585	promoter	abstract[184]|abstract[186]|person|abstract[188]	new[184]|giv[186]|giv|giv[188]	coref	21-29[190_188]
21-24	3586-3597	methylation	abstract[184]|abstract[186]|abstract[188]	new[184]|giv[186]|giv[188]	_	_
21-25	3598-3599	,	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
21-26	3600-3602	i.	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
21-27	3603-3605	e.	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
21-28	3606-3607	,	_	_	_	_
21-29	3608-3617	increased	abstract[190]	giv[190]	coref	25-20[234_190]
21-30	3618-3621	DNA	substance|abstract[190]	giv|giv[190]	coref	25-20
21-31	3622-3633	methylation	abstract[190]	giv[190]	_	_
21-32	3634-3636	in	abstract[190]	giv[190]	_	_
21-33	3637-3641	gene	abstract[190]|object[191]	giv[190]|giv[191]	_	_
21-34	3642-3648	bodies	abstract[190]|object[191]	giv[190]|giv[191]	_	_
21-35	3649-3652	may	_	_	_	_
21-36	3653-3660	promote	_	_	_	_
21-37	3661-3674	transcription	abstract	new	_	_
21-38	3675-3676	.	_	_	_	_

#Text=In this study , we compared the expression profiles of NFPAs and normal pituitary sections without evidence of neoplastic features , obtained by Rathke ’s cleft cyst surgery .
22-1	3677-3679	In	_	_	_	_
22-2	3680-3684	this	abstract[193]	giv[193]	_	_
22-3	3685-3690	study	abstract[193]	giv[193]	_	_
22-4	3691-3692	,	_	_	_	_
22-5	3693-3695	we	person	giv	ana	23-3
22-6	3696-3704	compared	_	_	_	_
22-7	3705-3708	the	object[196]	new[196]	_	_
22-8	3709-3719	expression	abstract|object[196]	giv|new[196]	coref	23-14[210_0]
22-9	3720-3728	profiles	object[196]	new[196]	_	_
22-10	3729-3731	of	object[196]	new[196]	_	_
22-11	3732-3737	NFPAs	object[196]|object|abstract[198]	new[196]|giv|new[198]	coref|coref	27-12|27-12[249_198]
22-12	3738-3741	and	object[196]|abstract[198]	new[196]|new[198]	_	_
22-13	3742-3748	normal	object[196]|abstract[198]|plant[200]	new[196]|new[198]|giv[200]	_	_
22-14	3749-3758	pituitary	object[196]|abstract[198]|person|plant[200]	new[196]|new[198]|giv|giv[200]	coref	27-14
22-15	3759-3767	sections	object[196]|abstract[198]|plant[200]	new[196]|new[198]|giv[200]	_	_
22-16	3768-3775	without	_	_	_	_
22-17	3776-3784	evidence	abstract[201]	new[201]	_	_
22-18	3785-3787	of	abstract[201]	new[201]	_	_
22-19	3788-3798	neoplastic	abstract[201]|abstract[202]	new[201]|new[202]	_	_
22-20	3799-3807	features	abstract[201]|abstract[202]	new[201]|new[202]	_	_
22-21	3808-3809	,	_	_	_	_
22-22	3810-3818	obtained	_	_	_	_
22-23	3819-3821	by	_	_	_	_
22-24	3822-3828	Rathke	person[203]|event[205]	new[203]|new[205]	ana	23-1[0_205]
22-25	3829-3831	’s	person[203]|event[205]	new[203]|new[205]	_	_
22-26	3832-3837	cleft	event[205]	new[205]	_	_
22-27	3838-3842	cyst	object|event[205]	new|new[205]	_	_
22-28	3843-3850	surgery	event[205]	new[205]	_	_
22-29	3851-3852	.	_	_	_	_

#Text=This allowed us to identify DEGs and investigate which of these genes exhibits methylation-dependent expression .
23-1	3853-3857	This	event	giv	_	_
23-2	3858-3865	allowed	_	_	_	_
23-3	3866-3868	us	person	giv	ana	24-2
23-4	3869-3871	to	_	_	_	_
23-5	3872-3880	identify	_	_	_	_
23-6	3881-3885	DEGs	abstract	new	coref	24-15
23-7	3886-3889	and	_	_	_	_
23-8	3890-3901	investigate	_	_	_	_
23-9	3902-3907	which	_	_	_	_
23-10	3908-3910	of	_	_	_	_
23-11	3911-3916	these	abstract[209]	giv[209]	coref	24-7[213_209]
23-12	3917-3922	genes	abstract[209]	giv[209]	_	_
23-13	3923-3931	exhibits	_	_	_	_
23-14	3932-3953	methylation-dependent	abstract[210]	giv[210]	coref	24-26[0_210]
23-15	3954-3964	expression	abstract[210]	giv[210]	_	_
23-16	3965-3966	.	_	_	_	_

#Text=When we compared the list of genes with methylation/expression correlation and the list of DEGs , most genes were hypermethylated with a fold change in expression corresponding to the sign of the correlation , e. g. , a gene with negative methylation/expression correlation that was hypermethylated and downregulated in tumors .
24-1	3967-3971	When	_	_	_	_
24-2	3972-3974	we	person	giv	ana	27-1
24-3	3975-3983	compared	_	_	_	_
24-4	3984-3987	the	abstract[212]	new[212]	_	_
24-5	3988-3992	list	abstract[212]	new[212]	_	_
24-6	3993-3995	of	abstract[212]	new[212]	_	_
24-7	3996-4001	genes	abstract[212]|abstract[213]	new[212]|giv[213]	coref	24-17[218_213]
24-8	4002-4006	with	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
24-9	4007-4029	methylation/expression	abstract[212]|abstract[213]|quantity|abstract[215]	new[212]|giv[213]|new|giv[215]	coref|coref	24-32[223_215]|24-42
24-10	4030-4041	correlation	abstract[212]|abstract[213]|abstract[215]	new[212]|giv[213]|giv[215]	_	_
24-11	4042-4045	and	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
24-12	4046-4049	the	abstract[212]|abstract[213]|object[216]	new[212]|giv[213]|new[216]	_	_
24-13	4050-4054	list	abstract[212]|abstract[213]|object[216]	new[212]|giv[213]|new[216]	_	_
24-14	4055-4057	of	abstract[212]|abstract[213]|object[216]	new[212]|giv[213]|new[216]	_	_
24-15	4058-4062	DEGs	abstract[212]|abstract[213]|object[216]|abstract	new[212]|giv[213]|new[216]|giv	coref	28-18
24-16	4063-4064	,	_	_	_	_
24-17	4065-4069	most	abstract[218]	giv[218]	coref	25-5[0_218]
24-18	4070-4075	genes	abstract[218]	giv[218]	_	_
24-19	4076-4080	were	_	_	_	_
24-20	4081-4096	hypermethylated	_	_	_	_
24-21	4097-4101	with	_	_	_	_
24-22	4102-4103	a	abstract[220]	new[220]	coref	25-9[230_220]
24-23	4104-4108	fold	place|abstract[220]	new|new[220]	_	_
24-24	4109-4115	change	abstract[220]	new[220]	_	_
24-25	4116-4118	in	_	_	_	_
24-26	4119-4129	expression	abstract	giv	coref	25-13
24-27	4130-4143	corresponding	_	_	_	_
24-28	4144-4146	to	_	_	_	_
24-29	4147-4150	the	abstract[222]	new[222]	coref	25-23[236_222]
24-30	4151-4155	sign	abstract[222]	new[222]	_	_
24-31	4156-4158	of	abstract[222]	new[222]	_	_
24-32	4159-4162	the	abstract[222]|abstract[223]	new[222]|giv[223]	coref	24-41[226_223]
24-33	4163-4174	correlation	abstract[222]|abstract[223]	new[222]|giv[223]	_	_
24-34	4175-4176	,	_	_	_	_
24-35	4177-4179	e.	_	_	_	_
24-36	4180-4182	g.	_	_	_	_
24-37	4183-4184	,	_	_	_	_
24-38	4185-4186	a	abstract[224]	giv[224]	_	_
24-39	4187-4191	gene	abstract[224]	giv[224]	_	_
24-40	4192-4196	with	abstract[224]	giv[224]	_	_
24-41	4197-4205	negative	abstract[224]|abstract[226]	giv[224]|giv[226]	coref	25-26[237_226]
24-42	4206-4228	methylation/expression	abstract[224]|quantity|abstract[226]	giv[224]|giv|giv[226]	coref	25-37
24-43	4229-4240	correlation	abstract[224]|abstract[226]	giv[224]|giv[226]	_	_
24-44	4241-4245	that	_	_	_	_
24-45	4246-4249	was	_	_	_	_
24-46	4250-4265	hypermethylated	_	_	_	_
24-47	4266-4269	and	_	_	_	_
24-48	4270-4283	downregulated	_	_	_	_
24-49	4284-4286	in	_	_	_	_
24-50	4287-4293	tumors	object	giv	coref	25-43
24-51	4294-4295	.	_	_	_	_

#Text=In a subset of genes , however , the fold change in expression was inconsistent with the difference in DNA methylation and the sign of the correlation , e. g. , a hypermethylated gene with negative methylation/expression correlation that was upregulated in tumors .
25-1	4296-4298	In	_	_	_	_
25-2	4299-4300	a	quantity[228]	new[228]	_	_
25-3	4301-4307	subset	quantity[228]	new[228]	_	_
25-4	4308-4310	of	quantity[228]	new[228]	_	_
25-5	4311-4316	genes	quantity[228]|abstract	new[228]|giv	coref	26-1[242_0]
25-6	4317-4318	,	_	_	_	_
25-7	4319-4326	however	_	_	_	_
25-8	4327-4328	,	_	_	_	_
25-9	4329-4332	the	abstract[230]	giv[230]	_	_
25-10	4333-4337	fold	abstract[230]	giv[230]	_	_
25-11	4338-4344	change	abstract[230]	giv[230]	_	_
25-12	4345-4347	in	abstract[230]	giv[230]	_	_
25-13	4348-4358	expression	abstract[230]|abstract	giv[230]|giv	_	_
25-14	4359-4362	was	_	_	_	_
25-15	4363-4375	inconsistent	_	_	_	_
25-16	4376-4380	with	_	_	_	_
25-17	4381-4384	the	abstract[232]	new[232]	_	_
25-18	4385-4395	difference	abstract[232]	new[232]	_	_
25-19	4396-4398	in	abstract[232]	new[232]	_	_
25-20	4399-4402	DNA	abstract[232]|abstract|abstract[234]|abstract[235]	new[232]|giv|giv[234]|giv[235]	coref|coref	27-24|27-23[254_234]
25-21	4403-4414	methylation	abstract[232]|abstract[234]|abstract[235]	new[232]|giv[234]|giv[235]	_	_
25-22	4415-4418	and	abstract[232]|abstract[235]	new[232]|giv[235]	_	_
25-23	4419-4422	the	abstract[232]|abstract[235]|abstract[236]	new[232]|giv[235]|giv[236]	_	_
25-24	4423-4427	sign	abstract[232]|abstract[235]|abstract[236]	new[232]|giv[235]|giv[236]	_	_
25-25	4428-4430	of	abstract[232]|abstract[235]|abstract[236]	new[232]|giv[235]|giv[236]	_	_
25-26	4431-4434	the	abstract[232]|abstract[235]|abstract[236]|abstract[237]	new[232]|giv[235]|giv[236]|giv[237]	appos	25-29[238_237]
25-27	4435-4446	correlation	abstract[232]|abstract[235]|abstract[236]|abstract[237]	new[232]|giv[235]|giv[236]|giv[237]	_	_
25-28	4447-4448	,	_	_	_	_
25-29	4449-4451	e.	abstract[238]	giv[238]	appos	25-32[239_238]
25-30	4452-4454	g.	abstract[238]	giv[238]	_	_
25-31	4455-4456	,	_	_	_	_
25-32	4457-4458	a	abstract[239]	giv[239]	_	_
25-33	4459-4474	hypermethylated	abstract[239]	giv[239]	_	_
25-34	4475-4479	gene	abstract[239]	giv[239]	_	_
25-35	4480-4484	with	abstract[239]	giv[239]	_	_
25-36	4485-4493	negative	abstract[239]	giv[239]	_	_
25-37	4494-4516	methylation/expression	abstract[239]|quantity	giv[239]|giv	_	_
25-38	4517-4528	correlation	abstract[239]	giv[239]	_	_
25-39	4529-4533	that	_	_	_	_
25-40	4534-4537	was	_	_	_	_
25-41	4538-4549	upregulated	_	_	_	_
25-42	4550-4552	in	_	_	_	_
25-43	4553-4559	tumors	object	giv	_	_
25-44	4560-4561	.	_	_	_	_

#Text=These genes were excluded from the functional GSEA .
26-1	4562-4567	These	abstract[242]	giv[242]	coref	27-9[247_242]
26-2	4568-4573	genes	abstract[242]	giv[242]	_	_
26-3	4574-4578	were	_	_	_	_
26-4	4579-4587	excluded	_	_	_	_
26-5	4588-4592	from	_	_	_	_
26-6	4593-4596	the	event[243]	giv[243]	_	_
26-7	4597-4607	functional	event[243]	giv[243]	_	_
26-8	4608-4612	GSEA	event[243]	giv[243]	_	_
26-9	4613-4614	.	_	_	_	_

#Text=We believe that the differential the expression of these genes in NFPAs and pituitary tissue was due to a mechanism distinct from aberrant DNA methylation , despite the fact that the expression levels of these genes were methylation-related .
27-1	4615-4617	We	person	giv	ana	28-4
27-2	4618-4625	believe	_	_	_	_
27-3	4626-4630	that	_	_	_	_
27-4	4631-4634	the	abstract[245]	new[245]	_	_
27-5	4635-4647	differential	abstract[245]	new[245]	_	_
27-6	4648-4651	the	abstract[246]	new[246]	coref	27-32[0_246]
27-7	4652-4662	expression	abstract[246]	new[246]	_	_
27-8	4663-4665	of	abstract[246]	new[246]	_	_
27-9	4666-4671	these	abstract[246]|abstract[247]	new[246]|giv[247]	coref	27-35[258_247]
27-10	4672-4677	genes	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
27-11	4678-4680	in	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
27-12	4681-4686	NFPAs	abstract[246]|abstract[247]|object|abstract[249]	new[246]|giv[247]|giv|giv[249]	coref	28-9[262_0]
27-13	4687-4690	and	abstract[246]|abstract[247]|abstract[249]	new[246]|giv[247]|giv[249]	_	_
27-14	4691-4700	pituitary	abstract[246]|abstract[247]|abstract[249]|abstract|object[251]	new[246]|giv[247]|giv[249]|giv|new[251]	_	_
27-15	4701-4707	tissue	abstract[246]|abstract[247]|abstract[249]|object[251]	new[246]|giv[247]|giv[249]|new[251]	_	_
27-16	4708-4711	was	_	_	_	_
27-17	4712-4715	due	_	_	_	_
27-18	4716-4718	to	_	_	_	_
27-19	4719-4720	a	abstract[252]	giv[252]	_	_
27-20	4721-4730	mechanism	abstract[252]	giv[252]	_	_
27-21	4731-4739	distinct	abstract[252]	giv[252]	_	_
27-22	4740-4744	from	_	_	_	_
27-23	4745-4753	aberrant	abstract[254]	giv[254]	coref	28-22[266_254]
27-24	4754-4757	DNA	abstract|abstract[254]	giv|giv[254]	_	_
27-25	4758-4769	methylation	abstract[254]	giv[254]	_	_
27-26	4770-4771	,	_	_	_	_
27-27	4772-4779	despite	_	_	_	_
27-28	4780-4783	the	abstract[255]	new[255]	_	_
27-29	4784-4788	fact	abstract[255]	new[255]	_	_
27-30	4789-4793	that	abstract[255]	new[255]	_	_
27-31	4794-4797	the	abstract[255]|abstract[257]	new[255]|new[257]	_	_
27-32	4798-4808	expression	abstract[255]|abstract|abstract[257]	new[255]|giv|new[257]	_	_
27-33	4809-4815	levels	abstract[255]|abstract[257]	new[255]|new[257]	_	_
27-34	4816-4818	of	abstract[255]|abstract[257]	new[255]|new[257]	_	_
27-35	4819-4824	these	abstract[255]|abstract[257]|abstract[258]	new[255]|new[257]|giv[258]	_	_
27-36	4825-4830	genes	abstract[255]|abstract[257]|abstract[258]	new[255]|new[257]|giv[258]	_	_
27-37	4831-4835	were	abstract[255]	new[255]	_	_
27-38	4836-4855	methylation-related	abstract[255]	new[255]	_	_
27-39	4856-4857	.	_	_	_	_

#Text=In general , our analysis showed that in gonadotroph NFPAs , the expression of 9 % of DEGs is correlated with aberrant methylation .
28-1	4858-4860	In	_	_	_	_
28-2	4861-4868	general	abstract	new	_	_
28-3	4869-4870	,	_	_	_	_
28-4	4871-4874	our	person|abstract[261]	giv|giv[261]	_	_
28-5	4875-4883	analysis	abstract[261]	giv[261]	_	_
28-6	4884-4890	showed	_	_	_	_
28-7	4891-4895	that	_	_	_	_
28-8	4896-4898	in	_	_	_	_
28-9	4899-4910	gonadotroph	object[262]	giv[262]	_	_
28-10	4911-4916	NFPAs	object[262]	giv[262]	_	_
28-11	4917-4918	,	_	_	_	_
28-12	4919-4922	the	abstract[263]	new[263]	_	_
28-13	4923-4933	expression	abstract[263]	new[263]	_	_
28-14	4934-4936	of	abstract[263]	new[263]	_	_
28-15	4937-4938	9	abstract[263]|quantity[264]	new[263]|new[264]	_	_
28-16	4939-4940	%	abstract[263]|quantity[264]	new[263]|new[264]	_	_
28-17	4941-4943	of	abstract[263]|quantity[264]	new[263]|new[264]	_	_
28-18	4944-4948	DEGs	abstract[263]|quantity[264]|abstract	new[263]|new[264]|giv	_	_
28-19	4949-4951	is	_	_	_	_
28-20	4952-4962	correlated	_	_	_	_
28-21	4963-4967	with	_	_	_	_
28-22	4968-4976	aberrant	abstract[266]	giv[266]	_	_
28-23	4977-4988	methylation	abstract[266]	giv[266]	_	_
28-24	4989-4990	.	_	_	_	_
